A detailed history of Brooks, Moore & Associates, Inc. transactions in Abbott Laboratories stock. As of the latest transaction made, Brooks, Moore & Associates, Inc. holds 38,792 shares of ABT stock, worth $4 Million. This represents 2.84% of its overall portfolio holdings.

Number of Shares
38,792
Previous 39,405 1.56%
Holding current value
$4 Million
Previous $4.34 Million 1.66%
% of portfolio
2.84%
Previous 3.02%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$109.52 - $120.96 $67,135 - $74,148
-613 Reduced 1.56%
38,792 $4.41 Million
Q4 2023

Feb 15, 2024

SELL
$90.19 - $110.4 $21,645 - $26,496
-240 Reduced 0.61%
39,405 $4.34 Million
Q3 2023

Nov 15, 2023

SELL
$95.53 - $114.62 $19,106 - $22,924
-200 Reduced 0.5%
39,645 $3.84 Million
Q2 2023

Aug 15, 2023

SELL
$100.78 - $112.29 $90,702 - $101,061
-900 Reduced 2.21%
39,845 $4.34 Million
Q1 2023

May 15, 2023

SELL
$96.86 - $114.01 $464,249 - $546,449
-4,793 Reduced 10.53%
40,745 $4.13 Million
Q4 2022

Feb 03, 2023

BUY
$95.06 - $111.52 $28,518 - $33,456
300 Added 0.66%
45,538 $5 Million
Q3 2022

Nov 17, 2022

SELL
$96.76 - $112.03 $29,028 - $33,609
-300 Reduced 0.66%
45,238 $4.38 Million
Q2 2022

Aug 04, 2022

SELL
$102.07 - $123.37 $17,249 - $20,849
-169 Reduced 0.37%
45,538 $4.95 Million
Q1 2022

May 03, 2022

SELL
$114.02 - $139.04 $38,766 - $47,273
-340 Reduced 0.74%
45,707 $5.41 Million
Q4 2021

Feb 04, 2022

SELL
$115.53 - $141.46 $43,323 - $53,047
-375 Reduced 0.81%
46,047 $6.48 Million
Q3 2021

Nov 08, 2021

SELL
$116.66 - $129.06 $23,332 - $25,812
-200 Reduced 0.43%
46,422 $5.48 Million
Q2 2021

Jul 21, 2021

BUY
$105.79 - $124.53 $31,737 - $37,359
300 Added 0.65%
46,622 $5.41 Million
Q1 2021

May 04, 2021

BUY
$108.84 - $128.23 $7,074 - $8,334
65 Added 0.14%
46,322 $5.55 Million
Q4 2020

Feb 08, 2021

SELL
$105.0 - $114.42 $56,700 - $61,786
-540 Reduced 1.15%
46,257 $5.07 Million
Q3 2020

Nov 02, 2020

SELL
$91.64 - $111.29 $75,603 - $91,814
-825 Reduced 1.73%
46,797 $5.09 Million
Q2 2020

Aug 10, 2020

SELL
$76.57 - $98.0 $507,276 - $649,250
-6,625 Reduced 12.21%
47,622 $4.35 Million
Q1 2020

Apr 22, 2020

SELL
$62.82 - $91.86 $100,386 - $146,792
-1,598 Reduced 2.86%
54,247 $4.28 Million
Q4 2019

Jan 30, 2020

SELL
$78.51 - $87.4 $37,292 - $41,515
-475 Reduced 0.84%
55,845 $4.85 Million
Q3 2019

Oct 25, 2019

SELL
$81.84 - $88.74 $106,555 - $115,539
-1,302 Reduced 2.26%
56,320 $4.71 Million
Q2 2019

Aug 09, 2019

SELL
$72.88 - $85.0 $455,500 - $531,250
-6,250 Reduced 9.79%
57,622 $4.85 Million
Q1 2019

Apr 24, 2019

SELL
$66.22 - $80.06 $611,872 - $739,754
-9,240 Reduced 12.64%
63,872 $5.11 Million
Q4 2018

Feb 06, 2019

BUY
$65.56 - $74.27 $4.79 Million - $5.43 Million
73,112 New
73,112 $5.29 Million

Others Institutions Holding ABT

About ABBOTT LABORATORIES


  • Ticker ABT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 1,751,219,968
  • Market Cap $180B
  • Description
  • Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for t...
More about ABT
Track This Portfolio

Track Brooks, Moore & Associates, Inc. Portfolio

Follow Brooks, Moore & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brooks, Moore & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brooks, Moore & Associates, Inc. with notifications on news.